Immatics (NASDAQ:IMTXW – Get Free Report) was down 0.7% on Monday . The stock traded as low as $0.19 and last traded at $0.19. Approximately 2,133 shares were traded during trading, a decline of 87% from the average daily volume of 15,892 shares. The stock had previously closed at $0.19.
Immatics Stock Performance
The firm has a 50 day moving average of $0.66 and a two-hundred day moving average of $2.00.
Immatics Company Profile
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
See Also
- Five stocks we like better than Immatics
- 3 Fintech Stocks With Good 2021 Prospects
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 2 Drone Stocks Surging from Increased Media Attention
- The How and Why of Investing in Gold Stocks
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.
